RCEL

SEC source: 0001193125-26-269544 · ownership.xml · nonDerivative · entry 1

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 152,927

F1 · balance_after: Includes unvested RSUs

SEC source: 0001193125-26-363747 · ownership.xml · nonDerivative · entry 1

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 152,927

F1 · kind: The original Form 4, filed on June 12, 2026, inadvertently used transaction code 'A' instead of transaction code 'P'. This amendment corrects the transaction code.

F2 · balance_after: Includes unvested RSUs

SEC source: 0001193125-26-263968 · ownership.xml · nonDerivative · entry 2

Woody Joseph Fralin · CIK 0001709989 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,761

F1 · balance_after: Includes unvested RSUs

SEC source: 0001193125-26-263968 · ownership.xml · nonDerivative · entry 1

Woody Joseph Fralin · CIK 0001709989 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,761

F1 · balance_after: Includes unvested RSUs

SEC source: 0001193125-26-266397 · ownership.xml · nonDerivative · entry 1

Woody Joseph Fralin · CIK 0001709989 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,961

F1 · balance_after: Includes unvested RSUs

SEC source: 0001709989-26-000011 · ownership.xml · nonDerivative · entry 2

Woody Joseph Fralin · CIK 0001709989 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,761

F1 · balance_after: Includes unvested RSUs

SEC source: 0001709989-26-000011 · ownership.xml · nonDerivative · entry 1

Woody Joseph Fralin · CIK 0001709989 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,761

F1 · balance_after: Includes unvested RSUs

SEC source: 0001709989-26-000006 · ownership.xml · nonDerivative · entry 4

Woody Joseph Fralin · CIK 0001709989 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

SEC source: 0001709989-26-000006 · ownership.xml · nonDerivative · entry 3

Woody Joseph Fralin · CIK 0001709989 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

SEC source: 0001709989-26-000006 · ownership.xml · nonDerivative · entry 2

Woody Joseph Fralin · CIK 0001709989 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

SEC source: 0001709989-26-000006 · ownership.xml · nonDerivative · entry 1

Woody Joseph Fralin · CIK 0001709989 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

SEC source: 0001193125-26-251586 · ownership.xml · nonDerivative · entry 1

Vance Cary Guy · CIK 0001608992 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,771

F1 · shares: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2025 and ended on May 31, 2026 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on December 1, 2025 (the purchase date of the offering period).

F1 · price: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2025 and ended on May 31, 2026 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on December 1, 2025 (the purchase date of the offering period).

F2 · balance_after: Includes unvested RSUs.

SEC source: 0001193125-26-251588 · ownership.xml · nonDerivative · entry 1

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,927

F1 · shares: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2025 and ended on May 31, 2026 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on December 1, 2025 (the purchase date of the offering period).

F1 · price: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2025 and ended on May 31, 2026 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on December 1, 2025 (the purchase date of the offering period).

F2 · balance_after: Includes unvested RSUs

SEC source: 0001193125-26-232686 · ownership.xml · nonDerivative · entry 1

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 145,927

F1 · balance_after: Includes unvested RSUs

SEC source: 0001193125-26-230874 · ownership.xml · nonDerivative · entry 1

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 143,927

F1 · balance_after: Includes unvested RSUs

SEC source: 0001193125-26-102263 · ownership.xml · nonDerivative · entry 1

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 141,927

F1 · balance_after: Includes unvested RSUs

SEC source: 0001193125-26-064111 · ownership.xml · nonDerivative · entry 1

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,127

F1 · balance_after: Includes unvested RSUs.

SEC source: 0001193125-26-059552 · ownership.xml · derivative · entry 2

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,510

Underlying: Common Stock · 155,510 shares

Expires 2036-02-18

F3 · derivative.exercise_date: These Stock Options vest in three equal annual installments beginning the first anniversary of the grant date of February 18, 2026.

SEC source: 0001193125-26-059552 · ownership.xml · nonDerivative · entry 1

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,127

F1 · price: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest in three equal annual installments beginning on the date 12 months following the grant date of February 18, 2026.

F2 · balance_after: Includes unvested RSUs.

SEC source: 0001193125-26-059502 · ownership.xml · derivative · entry 2

KELSEY NICOLE · CIK 0001714653 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 145,060

Underlying: Common Stock · 145,060 shares

Expires 2036-02-18

F3 · derivative.exercise_date: These Stock Options vest in three equal annual installments beginning the first anniversary of the grant date of February 18, 2026.

SEC source: 0001193125-26-059502 · ownership.xml · nonDerivative · entry 1

KELSEY NICOLE · CIK 0001714653 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 98,390

F1 · price: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest in three equal annual installments beginning on the date 12 months following the grant date of February 18, 2026.

F2 · balance_after: Includes unvested RSUs.

SEC source: 0001124181-26-000002 · ownership.xml · derivative · entry 2

REED JAN STERN · CIK 0001124181 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,133

Underlying: Common Stock · 16,133 shares

Expires 2036-01-20

F3 · derivative.exercise_price: On January 5, 2026, the Board of Directors approved a grant of 16,133 options to acquire 16,133 shares of Common Stock to each of its non-executive directors, with a grant date of January 20, 2026 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.

SEC source: 0001124181-26-000002 · ownership.xml · nonDerivative · entry 1

REED JAN STERN · CIK 0001124181 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,225

F1 · price: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 20, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.

F2 · balance_after: Includes unvested RSUs.

SEC source: 0001816242-26-000002 · ownership.xml · derivative · entry 2

Crowe Suzanne · CIK 0001816242 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,133

Underlying: Common Stock · 16,133 shares

Expires 2036-01-20

F4 · derivative.exercise_price: On January 5, 2026, the Board of Directors approved a grant of 16,133 options to acquire 16,133 shares of Common Stock to each of its non-executive directors, with a grant date of January 20, 2026 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.

SEC source: 0001816242-26-000002 · ownership.xml · nonDerivative · entry 1

Crowe Suzanne · CIK 0001816242 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,148

F1 · price: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 20, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.

F2 · balance_after: Includes unvested RSUs.

F3 · balance_after: Includes 22,990 of the Issuer's CDIs. The Reporting Person's 22,990 CDIs translate into 4,598 of the shares of Common Stock set forth above.

SEC source: 0001709989-26-000008 · ownership.xml · derivative · entry 4

Woody Joseph Fralin · CIK 0001709989 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,133

Underlying: Common Stock · 16,133 shares

Expires 2036-01-20

F6 · derivative.exercise_price: On January 5, 2026, the Board of Directors approved a grant of 16,133 options to acquire 16,133 shares of Common Stock to each of its non-executive directors, with a grant date of January 20, 2026 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.

SEC source: 0001709989-26-000008 · ownership.xml · nonDerivative · entry 2

Woody Joseph Fralin · CIK 0001709989 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,761

F3 · price: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 20, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.

F2 · balance_after: Includes unvested RSUs

SEC source: 0001216486-26-000002 · ownership.xml · derivative · entry 2

COOK JEREMY CURNOCK · CIK 0001216486 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,133

Underlying: Common Stock · 16,133 shares

Expires 2036-01-20

F3 · derivative.exercise_price: On January 5, 2026, the Board of Directors approved a grant of 16,133 options to acquire 16,133 shares of Common Stock to each of its non-executive directors, with a grant date of January 20, 2026 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.

SEC source: 0001216486-26-000002 · ownership.xml · nonDerivative · entry 1

COOK JEREMY CURNOCK · CIK 0001216486 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,050

F1 · price: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 20, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.

F2 · balance_after: Includes unvested RSUs.

SEC source: 0001387652-26-000001 · ownership.xml · derivative · entry 2

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,133

Underlying: Common Stock · 16,133 shares

Expires 2036-01-20

F3 · derivative.exercise_price: On January 5, 2026, the Board of Directors approved a grant of 16,133 options to acquire 16,133 shares of Common Stock to each of its non-executive directors, with a grant date of January 20, 2026 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.

SEC source: 0001387652-26-000001 · ownership.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,985

F1 · price: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 20, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.

F2 · balance_after: Includes unvested RSUs.

SEC source: 0001603289-26-000002 · ownership.xml · derivative · entry 4

Tarnoff Michael E · CIK 0001603289 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,133

Underlying: Common Stock · 16,133 shares

Expires 2036-01-20

F6 · derivative.exercise_price: On January 5, 2026, the Board of Directors approved a grant of 16,133 options to acquire 16,133 shares of Common Stock to each of its non-executive directors, with a grant date of January 20, 2026 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.

SEC source: 0001603289-26-000002 · ownership.xml · nonDerivative · entry 2

Tarnoff Michael E · CIK 0001603289 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,464

F3 · price: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 20, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.

F2 · balance_after: Includes unvested RSUs

SEC source: 0001709989-26-000008 · ownership.xml · derivative · entry 3

Woody Joseph Fralin · CIK 0001709989 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,446

Underlying: Common Stock · 29,446 shares

Expires 2036-01-05

F4 · derivative.exercise_price: On January 5, 2026, the Board of Directors approved a grant of 29,446 options to acquire 29,446 shares of Common Stock of the Company to Mr. Woody as a new non-executive director, with an effective grant date of January 5, 2026 and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on January 5, 2026 of $3.47. The grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.

F5 · derivative.exercise_date: These Stock Options vest in three equal annual installments beginning the first anniversary of the grant date.

SEC source: 0001709989-26-000008 · ownership.xml · nonDerivative · entry 1

Woody Joseph Fralin · CIK 0001709989 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,547

F1 · price: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest in three equal annual installments on the date 12 months following the grant date of January 5, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.

F2 · balance_after: Includes unvested RSUs

SEC source: 0000950170-25-112234 · ownership.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,771

F1 · balance_after: Includes unvested RSUs

SEC source: 0000950170-25-111467 · ownership.xml · nonDerivative · entry 1

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,657

SEC source: 0000950170-25-110499 · ownership.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,771

SEC source: 0000950170-25-107387 · ownership.xml · nonDerivative · entry 1

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,657

SEC source: 0001603289-26-000002 · ownership.xml · derivative · entry 3

Tarnoff Michael E · CIK 0001603289 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,063

Underlying: Common Stock · 19,063 shares

Expires 2035-08-06

F4 · derivative.exercise_price: On August 6, 2025, the Board of Directors approved a grant of 19,063 options to acquire 19,063 shares of Common Stock of the Company to Dr. Tarnoff as a new non-executive director, with an effective grant date of August 6, 2025 and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on August 6, 2025 of $5.36. The grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.

F5 · derivative.exercise_date: These Stock Options vest in three equal annual installments beginning the first anniversary of the grant date.

SEC source: 0001603289-26-000002 · ownership.xml · nonDerivative · entry 1

Tarnoff Michael E · CIK 0001603289 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,250

F1 · price: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest in three equal annual installments on the date 12 months following the grant date of August 6, 2025. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.

F2 · balance_after: Includes unvested RSUs

SEC source: 0000950170-25-080304 · ownership.xml · nonDerivative · entry 1

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,657

F1 · shares: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2024 and ended on May 31, 2025 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on May 30, 2025 (the purchase date of the offering period).

F1 · price: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2024 and ended on May 31, 2025 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on May 30, 2025 (the purchase date of the offering period).

SEC source: 0000950170-25-036355 · ownership.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,749

F1 · balance_after: Includes unvested RSUs

SEC source: 0000950170-25-024204 · ownership.xml · nonDerivative · entry 1

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,734

SEC source: 0000950170-25-024211 · ownership.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,749

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.89 to $10.19. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares of Common Stock purchased at each separate price within the ranges set forth in this footnote to this Form 4.

F2 · balance_after: Includes unvested RSUs

SEC source: 0000950170-25-023233 · ownership.xml · nonDerivative · entry 1

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,734

SEC source: 0000950170-25-007794 · ownership.xml · derivative · entry 1

O'Toole David D · CIK 0001491140 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2034-01-21

F1 · derivative.exercise_date: These Stock Options vest in three equal annual installments beginning the first anniversary of the grant date.

SEC source: 0000950170-25-007793 · ownership.xml · derivative · entry 1

KELSEY NICOLE · CIK 0001714653 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2034-01-21

F1 · derivative.exercise_date: These Stock Options vest in three equal annual installments beginning the first anniversary of the grant date.

SEC source: 0000950170-25-082450 · ownership.xml · derivative · entry 2

REED JAN STERN · CIK 0001124181 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,295

Underlying: Common Stock · 4,295 shares

Expires 2035-01-21

F3 · derivative.exercise_price: On January 6, 2025, the Board of Directors approved a grant of 4,295 options to acquire 4,295 shares of Common Stock to each of its non-executive directors, with a grant date of January 21, 2025 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $8.73. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025.

SEC source: 0000950170-25-082450 · ownership.xml · nonDerivative · entry 1

REED JAN STERN · CIK 0001124181 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,011

F1 · price: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 21, 2025. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025.

F2 · balance_after: Includes unvested RSUs.